search
Back to results

Melatonin Impact on the Outcomes of Myocardial Ischemia/Reperfusion Injury During Coronary Artery Bypass Grafting Surgery

Primary Purpose

Coronary Artery Bypass Grafting, Coronary Artery Disease

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Melatonin
placebo
Sponsored by
Ain Shams University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Coronary Artery Bypass Grafting focused on measuring CABG, melatonin, inflammation

Eligibility Criteria

30 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients who will undergo elective CABG,
  • ready to participate in the study and
  • can be reached by phone

Exclusion Criteria:

  • • Patients who will require urgent surgery and won't have adequate time to take medications for 5 days,

    • Re-operative patients (CABG),
    • Off-pump CABG,
    • Patients who have concomitant renal failure,
    • Patients with severe respiratory problems.
    • Patients with previous stroke or significant cerebrovascular disease,
    • Patients with hepatitis b,c and HIV.
    • Inflammatory disease ex. Rheumatoid arthritis, psoriasis…,
    • Patients with ejection fraction (EF%) lower than 40%,
    • Patients undergo CABG surgery with simultaneous heart valve repair or replacement, resection of a ventricular aneurysm, or other operations.
    • Pregnancy and lactation.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Placebo Comparator

    Arm Label

    Melatonin group

    Control group

    Arm Description

    Melatonin Group (n=11) patients will receive 60 mg/day Melatonin capsule (M1) from the day five before surgery.

    Control group (n=11) patients will receive placebos with the same appearances and packaging at the same dose and time as those in the melatonin group.

    Outcomes

    Primary Outcome Measures

    Nuclear factor-kB (NF-κB)
    Nuclear factor-kappa B (NF-κB) is a ubiquitous transcription factor that is involved in inflammatory and immune responses, as well as in regulation of expression of many other genes related to cell survival, proliferation, and differentiation

    Secondary Outcome Measures

    interleukin 6 il-6
    Interleukin-6 is a widely used cytokine that causes inflammation and oxidative stress, which would further result in cardiac and cerebral injury. The increased expression of interleukin-6 is closely related to atherosclerosis, myocardial infarction, heart failure and ischemic stroke. It is a key risk factor for these diseases by triggering inflammatory reaction and inducing other molecules release.
    Tumor necrosis factor alpha TNF-α
    Tumor necrosis factor (TNF) is a multifunctional cytokine that plays important roles in diverse cellular events such as cell survival, proliferation, differentiation, and death. As a pro-inflammatory cytokine, TNF is secreted by inflammatory cells, which may be involved in inflammation-associated heart diseases.
    cardiac troponins
    cardiac marker

    Full Information

    First Posted
    September 21, 2022
    Last Updated
    September 21, 2022
    Sponsor
    Ain Shams University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05552586
    Brief Title
    Melatonin Impact on the Outcomes of Myocardial Ischemia/Reperfusion Injury During Coronary Artery Bypass Grafting Surgery
    Official Title
    The Effect of Melatonin on the Outcomes of Myocardial Ischemia/Reperfusion Injury During Coronary Artery Bypass Grafting Surgery
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2022
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    October 2022 (Anticipated)
    Primary Completion Date
    July 2023 (Anticipated)
    Study Completion Date
    September 2023 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Ain Shams University

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    The ischemia/reperfusion (I/R) injury of the myocardium initiates a variety and complex sets of inflammatory reactions that may both exaggerate local injury as well as provoke injury of distant organ function . I/R injuries are the main causes of heart failure, morbidity, and mortality after cardiac surgery such as coronary artery bypass graft (CABG surgery) . The reactive oxygen species are believed to be excessively elevated during coronary artery bypass surgery (CABG) due to compromised free radical scavenging mechanism in the myocardium that can make myocardium highly susceptible to oxidative stress and inflammation and result in reperfusion injury . Melatonin and its metabolites protect against inflammation by regulating several inflammatory cytokines. Additionally, melatonin is a free radical scavenger and an antioxidant agent. the current study is designed to investigate the protective effects of melatonin against myocardial I/R injury in patients undergoing coronary artery bypass grafting (CABG) surgery.
    Detailed Description
    Myocardial ischemia is a situation where there is an inadequate blood and oxygen supply to the heart muscles due to partial or complete obstruction of the coronary arteries, predisposing the affected cardiac muscle to death. Hence, restoration of blood supply is critical to reestablish myocardial reperfusion. The ischemia/reperfusion (I/R) injury of the myocardium initiates a variety and complex sets of inflammatory reactions that may both exaggerate local injury as well as provoke injury of distant organ function . I/R injuries are the main causes of heart failure, morbidity, and mortality after cardiac surgery such as coronary artery bypass graft (CABG surgery) . The reactive oxygen species are believed to be excessively elevated during coronary artery bypass surgery (CABG) due to compromised free radical scavenging mechanism in the myocardium that can make myocardium highly susceptible to oxidative stress and inflammation and result in reperfusion injury . Strategies to improve the CABG related complications are much needed to augment the positive outcomes in the post-operative surviving patients. There are various therapeutic approaches to decrease or ameliorate myocardial I/R injury, these include reperfusion controlling, cardioprotective events and management via various interventions. Melatonin (N-acetyl 5-methoxy-tryptamine) is mainly secreted by the pineal gland to regulate sleep. Since 1993 when melatonin was first reported, a wide range of melatonin functions have been directly confirmed by multiple scientific studies . Melatonin and its metabolites protect against inflammation by regulating several inflammatory cytokines. Additionally, melatonin is a free radical scavenger and an antioxidant agent. Early studies have shown that melatonin exerts beneficial effects in the context of renal I/R, myocardial I/R, and hepatic I/R. The ability to protect against I/R injury may relate to the functions of melatonin as both an anti-inflammatory and an antioxidant agent . Some authors show an anti-apoptotic action of melatonin in different organs of the body, such as thymus, kidney, brain and liver . the current study is designed to investigate the protective effects of melatonin against myocardial I/R injury in patients undergoing coronary artery bypass grafting (CABG) surgery.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Coronary Artery Bypass Grafting, Coronary Artery Disease
    Keywords
    CABG, melatonin, inflammation

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    22 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Melatonin group
    Arm Type
    Active Comparator
    Arm Description
    Melatonin Group (n=11) patients will receive 60 mg/day Melatonin capsule (M1) from the day five before surgery.
    Arm Title
    Control group
    Arm Type
    Placebo Comparator
    Arm Description
    Control group (n=11) patients will receive placebos with the same appearances and packaging at the same dose and time as those in the melatonin group.
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Melatonin
    Intervention Description
    patients in the melatonin group will receive 60 mg/day Melatonin capsule (M1) from the day five before surgery.
    Intervention Type
    Other
    Intervention Name(s)
    placebo
    Intervention Description
    patients will receive capsules of the same size and color
    Primary Outcome Measure Information:
    Title
    Nuclear factor-kB (NF-κB)
    Description
    Nuclear factor-kappa B (NF-κB) is a ubiquitous transcription factor that is involved in inflammatory and immune responses, as well as in regulation of expression of many other genes related to cell survival, proliferation, and differentiation
    Time Frame
    24 hours
    Secondary Outcome Measure Information:
    Title
    interleukin 6 il-6
    Description
    Interleukin-6 is a widely used cytokine that causes inflammation and oxidative stress, which would further result in cardiac and cerebral injury. The increased expression of interleukin-6 is closely related to atherosclerosis, myocardial infarction, heart failure and ischemic stroke. It is a key risk factor for these diseases by triggering inflammatory reaction and inducing other molecules release.
    Time Frame
    24 hours
    Title
    Tumor necrosis factor alpha TNF-α
    Description
    Tumor necrosis factor (TNF) is a multifunctional cytokine that plays important roles in diverse cellular events such as cell survival, proliferation, differentiation, and death. As a pro-inflammatory cytokine, TNF is secreted by inflammatory cells, which may be involved in inflammation-associated heart diseases.
    Time Frame
    24 hours
    Title
    cardiac troponins
    Description
    cardiac marker
    Time Frame
    24 hours
    Other Pre-specified Outcome Measures:
    Title
    LVEF%
    Description
    left ventricular ejection fraction
    Time Frame
    24 hours
    Title
    Safety (Adverse effects from melatonin)
    Description
    Safety of melatonin
    Time Frame
    5 days
    Title
    hospital length of stay
    Description
    Duration of staying in hospital
    Time Frame
    5-7 days
    Title
    ICU length of stay
    Description
    Duration of staying in ICU
    Time Frame
    2-3 days

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    30 Years
    Maximum Age & Unit of Time
    70 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Patients who will undergo elective CABG, ready to participate in the study and can be reached by phone Exclusion Criteria: • Patients who will require urgent surgery and won't have adequate time to take medications for 5 days, Re-operative patients (CABG), Off-pump CABG, Patients who have concomitant renal failure, Patients with severe respiratory problems. Patients with previous stroke or significant cerebrovascular disease, Patients with hepatitis b,c and HIV. Inflammatory disease ex. Rheumatoid arthritis, psoriasis…, Patients with ejection fraction (EF%) lower than 40%, Patients undergo CABG surgery with simultaneous heart valve repair or replacement, resection of a ventricular aneurysm, or other operations. Pregnancy and lactation.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    eman A. casper, masters
    Phone
    0201068731483
    Email
    drcasper912009@hotmail.com
    First Name & Middle Initial & Last Name or Official Title & Degree
    sara M. Farid, PhD
    Phone
    01001232067
    Email
    sarah.farid@pharma.asu.edu.eg
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    eman A. casper, masters
    Organizational Affiliation
    Ain shams university , faculty of pharmacy
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    Undecided

    Learn more about this trial

    Melatonin Impact on the Outcomes of Myocardial Ischemia/Reperfusion Injury During Coronary Artery Bypass Grafting Surgery

    We'll reach out to this number within 24 hrs